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                                                        INTRODUCTION
Benign prostatic hyperplasia (BPH), one of the most common diseases of aging men, 
can be associated with bothersome lower urinary tract symptoms (LUTS) that affect quality of  
life  by  interfering  with  normal  daily  activities  and  sleep  patterns.  The  prevalence  of 
histopathologic BPH is age dependent, with initial development usually after 40 years of age. 
By 60 years of age, its prevalence is greater than 50% and by age 85 is as high as 90%.
Approximately one half of all men who have a histological diagnosis have moderate to 
severe  LUTS.  Because  long-term  data  from  population-based  studies  have  only  recently 
become available, the risks of developing complications and morbidities from untreated BPH 
are  unclear.  For  example,  despite  recent  evidence,  there  is  still  uncertainty  regarding  the 
likelihood  that  a  patient  with  a  specific  symptom complex  will  develop  complete  urinary 
retention within a particular time frame. Nonetheless,  BPH-associated mortality is  rare and 
serious complications are uncommon.
              In contrast, LUTS are bothersome to many patients, and the amount of bother may  
differ greatly among individuals with the same degree of symptom frequency and severity. 
Since the impact of LUTS on the patient's quality of life is 
highly variable and not directly related to any measurable physiological factors, the patient's 
perception of the severity of the condition, as well as the degree to which it interferes with his 
lifestyle or causes embarrassment, should be the primary consideration in choosing therapy
              These symptoms impair physiological and functional well-being, and interfere with  
daily  living.  Although  BPH  rarely  threatens  life,  it  can  contribute  to  acute  urological 
complications, particularly acute urinary retention (AUR), which is often considered to be the 
most serious complication of BPH. 
              AUR is relatively common, painful and distressing for the patient. Early estimates of  
incidence varied widely, but better estimates now available from population-based studies of 
men in the community indicate an incidence of 5–25 per 1000 person-years, or 0.5–2.5% per  
year. The risk is cumulative and increases with age.
              AUR is one of the main indications for TURP, reported as the precipitating reason for 
25–30% of emergency procedures. After an episode of spontaneous AUR (i.e. not caused by a 
specific event such as surgery, catheterization or drugs), 15% of patients in one long-term study 
had another episode of AUR, and 75% had subsequent surgery. The current management of 
AUR is  to  insert  a  urinary  catheter  to  relieve symptoms,  but  this  can add to  the  patient's 
symptoms if UTI develops. 
              In addition to being uncomfortable for the patient, this is an avoidable risk factor for  
blood loss after TURP, should surgery become necessary. A trial without catheter (TWOC) is 
considered  preferable  to  leaving  a  catheter  in  place;  success  rates  of  23–28%  have  been 
reported, but significant numbers of patients still require TURP.
              The  functional  symptoms  of  BPH can  be  reduced  by  α-blockers  such  as  
tamsulosin,Alfuzocin, which improve flow rates and bladder emptying, and it is thought likely 
that they also help to reduce bladder outlet resistance by effects on the sympathetic tone of the 
bladder neck and prostatic stroma. By reducing this  resistance,  provided the patient retains 
sufficient detrusor function, α-blockers could help relieve AUR and improve the chances of a 
successful TWOC. 
              The optimum duration of treatment with α-blockers has not been fully assessed, and  
there is controversy about the length of time the catheter should remain in situ for the initial  
treatment  phase.  One study suggested that  more prolonged use of  indwelling catheters  has 
better success rates for TWOC; immediate withdrawal had a 44% success rate compared with 
62% if the catheter was left for 7 days.[7]
            Acute urinary retention (AUR) is the presenting feature in 23–27% of men undergoing 
prostatectomy  for  benign  conditions.  The  increased  perioperative  mortality  and  morbidity 
observed in this group are in part due to an increased risk of sepsis and bleeding associated 
with urinary catheterization before surgery. It is therefore preferable that patients do not have 
urinary catheters at the time of prostatic surgery, and hence it is common practice for a patient  
to undergo a trial  without  catheter  (TWOC) after an administration of an alpha blocker to 
patients before a TWOC. The success rate of this TWOC is reportedly 23–28%, with 35% of 
those who are successful requiring prostatic surgery within 6 months
              Alfuzosin is a selective alpha1-adrenoceptor antagonist shown to have functional  
uroselectivity  .  It  effectively relieves  LUTS related to  BPO and the  sustained-release  (SR) 
formulation has been shown to have a urodynamic effect within 3 hours of first administration. 
Its good safety profile and rapid onset of action make it appropriate for use before a TWOC 
following AUR.
              There is now good evidence that giving the α-blocker alfuzosin to men with benign 
prostatic obstruction (BPO) before a trial without catheter (TWOC), after a first episode of 
acute urinary retention (AUR),  significantly improves the chances of a successful  return to 
voiding. Whilst up to 62% of patients will have a successful TWOC after receiving alfuzosin , 
little is known about the long-term outcome afterward. 
              Observational studies, conducted before medical therapy for BOO was widely  
available, provide some insight into what might be expected. In a retrospective study published 
in 1969, Craigen  et al. reported that during the 7-year follow-up 80% of 89 men who had 
presented with AUR caused by BPO required prostatic  surgery.[2]  Over  a decade later,  in 
another retrospective study, Breum et al. reported an incidence of surgery of 84% at 5 years 
within their cohort of 70 patients.[3]
              Prospective studies in this area are sparse and often provide a short follow-up of few  
patients. Klarskov et al. reported the longest follow-up to date in a prospective study of 1 year 
with a surgical intervention rate of 85%; in that study of 228 men with AUR they reported that  
factors predictive of preserved voiding ability after a successful TWOC were a retained volume 
of <500 ml, a maximum flow rate of >5 ml/s, and the presence of an event thought to provoke 
AUR. However, in that study most (75%) patients had a catheter passed to relieve their AUR; 
this was then removed immediately, rather than allowing a period of catheter drainage. This is 
an  important  observation,  as  it  has  been  reported  that  the  chance  of  a  successful  TWOC 
increases with the duration of catheter drainage.[7]
              Despite increased interest in the role of α-blockers for managing AUR there are no  
published prospective series of long-term outcome after a successful TWOC combined with an 
α-blocker.  We  sought  to  evaluate whether  administration  of  sustained  release  Alfuzocin 
improves the outcome of Trial Without Catheter (TWOC) compared to placebo after an episode 
of acute urinary retention (AUR) caused by Benign Prostatic Hyperplasia (BPH), and further 
comparing  the  recorded  variables  &  long-term  outcome  within  patients  recruited  to  a 
prospective study of the effect of alfuzosin on the outcome of a TWOC.
                                        OBJECTIVES
To evaluate whether administration of sustained release Alfuzocin improves the outcome 
of  Trial  Without  Catheter  (TWOC) compared to  placebo after  an episode of  acute  urinary 
retention (AUR) caused by Benign Prostatic Hyperplasia (BPH), by comparing the numbers of 
patients  who  voided  successfully  after  removing  their  catheter:  and  further  comparing  the 
recorded variables like 
Patient age,
           Initial catheterization volume after AUR,
            Prostate size,
            PVR after successful voiding
between those who had a successful  TWOC and those who did not  and identifying 
whether they are influencing the success of a trial without catheter (TWOC) and subsequent 
failure in the follow-up period.
REVIEW OF LITERATURE
BENIGN PROSTATIC HYPERPLASIA
BPH  is  one  of  the  causes  of  the  LUTS  in  aging  men  commonly  and,  probably 
incorrectly, referred to as prostatism. Histopathologically, BPH is characterized by an increased 
number of epithelial and stromal cells in the periurethral area of the prostate. The observation 
of new epithelial gland formation is normally seen only in fetal development and gives rise to 
the concept of embryonic reawakening of the stroma cell's inductive potential (Cunha et al, 
1983). The precise molecular etiology of this hyperplastic process is uncertain. The observed 
increase in cell numbers may be the result of epithelial and stromal proliferation or of impaired 
programmed  cell  death  leading  to  cellular  accumulation.  Androgens,  estrogens,  stromal-
epithelial interactions, growth factors, and neurotransmitters may play a role, either singly or in 
combination, in the etiology of the hyperplastic process. 
            Previously held notions that the clinical symptoms of BPH (prostatism) are caused 
simply by a mass-related increase in urethral resistance are too simplistic. It is now clear that a 
significant portion of LUTS is the result of age-related detrusor dysfunction. Moreover, bladder 
outlet obstruction itself may induce a variety of neural alterations in the bladder that contribute 
to symptomatology. Undoubtedly, the constellations of cellular pathologic processes that give 
rise to the symptoms of LUTS are far more complex than we currently realize. 
REGULATION OF PROSTATE GROWTH                  
Throughout life, the prostate responds to endocrine signals as it develops, undergoes a 
rapid phase of growth at puberty, maintains its size,  and, then, in some cases,  develops an 
abnormal growth with aging that may result in either benign or malignant disease. The cell  
kinetics  of  this  process  are  now being defined in  terms  of  the  dynamic  interplay  between 
growth-promoting and growth-suppressing factors and how they regulate a cell cycle of DNA 
synthesis and mitosis while balancing between a cycle of cellular death and apoptosis (see  
review by Denmeade and colleagues [1996]). 
            The kinetics and dynamics of cell replication and cell death in the human prostate are  
now being defined in quantitative numbers (Berges et al, 1995). Isaacs has defined the major  
step in the interaction of the cell cycle between growth and death. The net balance between the  
rate of cell growth and cell death maintains the steady-state size of the prostate; it appears to be 
under hormonal and growth factor control and is age dependent. Resolving the mechanisms 
that control this normal growth balance is most crucial to understanding the imbalance that 
occurs in tumor growth. [39]
ACUTE URINARY RETENTION 
Acute urinary retention (AUR) is one of the most significant complications or long-term 
outcomes  resulting  from BPH for  a  variety  of  reasons.  It  has,  in  the  past,  represented  an 
immediate indication for surgery. Between 25% and 30% of men who underwent TURP had 
AUR as their main indication in older series (Holtgrewe et al, 1989), and, today, most patients  
failing to void after an attempt of catheter removal still undergo surgery. For this reason alone,  
AUR is from an economic as well as a patient viewpoint an important and feared event. 
For the patient, it presents as the inability to urinate with increasing pain, eventually a 
visit to the emergency department, catheterization, follow-up visits to physicians, an attempt at 
catheter removal,  and eventually recovery or surgery, both a painful and a time-consuming 
process. In older literature, the risk of recurrent AUR was cited as being 56% to 64% within 1  
week of the first episode and 76% to 83% in men with diagnosed BPH (Breum et al, 1982;  
Klarskov et al 1987; Hastie et al, 1990).[3,6,33]
            The etiology of AUR is poorly understood. Prostate infection, bladder over distention 
(Powell et al, 1980), excessive fluid intake, alcohol consumption, sexual activity, debility, and 
bed rest have all been mentioned (Stimson and Fihn, 1990).
SPONTANEOUS VS PRECIPITATED AUR                   
From a clinical and prognostic point of view, spontaneous AUR should be separated 
from  precipitated  AUR,  although  this  is  by  no  means  consistently  done  in  the  literature. 
Precipitated AUR refers to the inability to urinate after a triggering event, such as non–prostate-
related surgery, catheterization, anesthesia, ingestion of medications with sympathomimetic or 
anticholinergic effects or antihistamines, or others. 
All other AUR episodes are classified as spontaneous (Roehrborn et al, 1999b, 2000). 
The importance of differentiating the two types of AUR becomes clear when evaluating the 
ultimate outcomes of patients. After spontaneous AUR, 15% of patients had another episode of 
spontaneous AUR and a total of 75% underwent surgery, whereas, after precipitated AUR, only 
9% had an episode of spontaneous AUR and 26% underwent surgery (Roehrborn et al, 2000).
[23]
THE BLADDER'S RESPONSE TO OBSTRUCTION 
Current  evidence  suggests  that  the  bladder's  response  to  obstruction  is  largely  an 
adaptive one. However, it is also clear that many of the clinical symptoms of prostatism are  
related to obstruction-induced changes in bladder function, rather than to outflow obstruction 
directly. Approximately one third of men continue to have significant voiding dysfunction after 
surgical relief of obstruction (Abrams et al, 1979). [29]
Obstruction-induced  changes  in  the  bladder  are  of  two  basic  types:            
             (1) those  changes that lead to detrusor instability or decreased compliance, which are  
clinically associated with symptoms of frequency and urgency, and
             (2) those changes associated with decreased detrusor contractility, which are associated 
with further deterioration in the force of the urinary stream, hesitancy, intermittency, increased 
residual urine, and (in a minority of cases) detrusor failure. 
Acute urinary retention should not be viewed as an inevitable result of this process. 
Many  patients  presenting  with  acute  urinary  retention  have  more  than  adequate  detrusor 
function, with evidence of a precipitating event leading to the obstruction.
Much  of  our  knowledge  of  the  detrusor's  response  to  obstruction  is  based  on 
experimental  animal  studies.  Limited information is  available  on the  natural  history  of  the 
human bladder's response to obstruction. Gosling has demonstrated that the major endoscopic 
detrusor  change,  trabeculation,  is  caused by an  increase  in  detrusor  collagen (Gosling and 
Dixon, 1980; Gosling et al, 1980). Severe trabeculation is associated with significant residual 
urine  (Barry  et  al,  1993),  suggesting  incomplete  emptying  may  be  the  result  of  increased 
collagen rather than impaired muscle function. Severe trabeculation, however, is seen in fairly 
advanced disease.
            In experimental animal models, the initial response of the detrusor to obstruction is the  
development of smooth muscle hypertrophy (Levin et al, 1995). It is likely that this increase in 
muscle mass, although an adaptive response to increased intravesical pressure and maintained 
flow, is associated with significant intracellular and extracellular changes in the smooth muscle 
cell that lead to detrusor instability. Obstruction also induces changes in smooth muscle cell 
contractile protein expression, energy production, and cell-to-cell communication (Levin et al, 
1995).
            In  experimental  animal  models,  unrelieved  obstruction  is  associated  with  the 
development of significant increases in detrusor extracellular matrix (collagen) (Levin et al, 
1995). This also appears to be the case in the human, although cause-and-effect relationships 
have  not  been  established  (Gosling  and  Dixon,  1980).  In  addition  to  obstruction-induced 
changes in the smooth muscle cell and extracellular matrix of the bladder, there is increasing 
evidence that obstruction may modulate neural-detrusor responses as well (Steers et al, 1990; 
Clemow et  al,  2000).  Altered  neural  control  of  micturition  has  been  noted  in  aging  rats, 
including  reduced  bladder  contractility,  impaired  central  processing,  and  altered  sensation 
(Chai et al, 2000).
INCIDENCE OF AUR IN BPH
Older estimates of occurrence of AUR range from 4 to 15 to as high as 130/1000 person-
years (calculated by Jacobsen et al, 1997 based on earlier studies [Craigen et al, 1969; Birkhoff 
et al, 1976; Ball et al, 1981]), which leads to 10-year cumulative incidence rates ranging from 
4% to 73%. The self-reported rate of AUR in a cross-sectional study in 2002 Spanish men was 
5.1% (Hunter et al, 1996). [2]
            During 15,851 person-years of follow-up in the Physicians Health Study, 82 men 
reported an episode of AUR, for an incidence rate of 4.5/1000 person-years (95% CI, 3.1 to 
6.2) (Meigs et al, 1999). Of the 2115 men aged 40 to 79 years in the Olmsted County study, 57 
had a first episode of AUR during 8344 person-years of follow-up (incidence, 6.8/1000 person-
years; 95% CI, 5.2 to 8.9) (Jacobsen et al, 1997). 
            The best data from men diagnosed with BPH stem from the PLESS (McConnell et al,  
1998). In PLESS, 1376 placebo-treated men with enlarged prostates and moderate symptoms 
had complete  follow-up over  4  years,  of  which  99 experienced an  episode  of  AUR for  a 
calculated incidence rate of 18/1000 person-years.[16,23] 
            Although age in community-dwelling men is an important risk factor, in a BPH trial  
population of men who already are diagnosed with BPH, other factors can be analyzed. In the 
placebo groups of three 2-year studies (Marberger et al, 2000) and a 4-year study (PLESS) 
(McConnell et al, 1998; Kaplan et al, 2000; Roehrborn et al, 1999b, 2000), prostate volume, 
serum PSA, and symptom severity all were predictors of AUR episodes. [23]
INDICATIONS FOR PROSTATECTOMY 
The indications for prostatectomy, by either open approach or transurethral resection, include 
                  (1) Refractory urinary retention; 
                  (2) recurrent or persistent urinary tract infections; 
                  (3) significant symptoms from bladder outlet obstruction not responsive to medical 
therapy;
                  (4) recurrent gross hematuria of prostatic origin; 
                  (5) renal insufficiency due to BPH; and 
                  (6) bladder calculi secondary to obstruction. 
Currently,  TURP accounts  for  over  90% of prostatectomies  performed for  benign prostatic 
hyperplasia. [39]
AUR AND SURGERY  
Both surgery and AUR represent distinct endpoints in the disease progression of BPH. 
There  are,  however,  distinct  differences.  AUR is  an  outcome mandating  management,  and 
surgery is one of the commonly employed management styles. AUR is probably one of the 
clearer  indications for  surgery,  leaving the treating physician little  choice in  a patient  who 
failed a trial without catheter. However, most patients undergo surgery not for AUR but for 
symptoms (Holtgrewe et al, 1989). 
Depending  on  local  practice  pattern,  AUR  accounts  for  5%  to  over  30%  of  the 
indications for surgery. AUR can be compared with a fracture. It is impossible for the physician 
during interaction with the patient to increase or decrease the probability for that outcome to 
occur. Furthermore, once it has occurred, no interaction or consultation can undo it. In contrast, 
it is easy to see how patients can be influenced in their decision to undergo surgery by the 
consultation with the physician. 
MEDICAL THERAPY FOR BPH 
Medical  therapies  investigated  for  BPH  include  α-adrenergic  blockers,  androgen 
suppression,  aromatase  inhibitors,  and  plant  extracts.  α-Adrenergic  blockers  and  androgen 
suppression are important because the safety and efficacy of drugs in these classes have been 
critically examined, and these drugs are widely prescribed for the treatment of BPH. Plant  
extracts are also widely used in some parts of the world despite the lack of properly designed 
clinical trials. Because plant extracts are not classified as drugs, the marketing and claims are 
not critically scrutinized by regulatory agencies.
THE IMPACT OF MEDICAL THERAPY 
Prior to the 1980s, prostatectomy was the only widely accepted intervention for BPH. 
The  enthusiasm  for  medical  therapy  has  been  supported  in  part  by  the  limitations  of 
prostatectomy, which include the morbidity of the surgical procedure, failure to consistently 
achieve a successful outcome, necessity for re treatment, and the suggestion that prostatectomy 
increases the risk of delayed life-threatening cardiac events (Lepor, 1993). Although medical 
therapies do not achieve the same level of efficacy as prostatectomy, the attractive features of 
medical therapy relative to prostatectomy are that clinically significant outcomes are obtained 
with fewer, less serious and reversible side effects (Lepor, 1993). Because the indication for 
intervention in the overwhelming majority of patients with BPH is to improve quality of life by 
relieving  symptoms  (Mebust  et  al,  1989),  the  lower  morbidity  of  medical  therapy  is  of 
paramount importance in patient-driven treatment decisions.
           Medical therapy is currently considered the preferred treatment alternative for those  
individuals who lack absolute indications for surgery. Because the overwhelming majority of 
men undergoing TURP lack absolute  indications  for  intervention (Mebust  et  al,  1989) and 
prefer non surgical options, the number of prostatectomies performed throughout the world has 
decreased. [25]
            A survey of  the  U.S.  Medicare database revealed that  the absolute  number of 
prostatectomies decreased from 250,000 in 1987 to 116,000 in 1996 to 88,000 in 2000 (Health 
Care Financing Administration, 1997). Similar reductions in TURPs have been reported from 
France, Canada, Denmark, and Germany (Holtgrewe, 1998).
SELECTING CANDIDATES FOR MEDICAL THERAPY 
The ideal candidate for medical therapy should have symptoms that are bothersome and 
negatively affect quality of life. The finding of a "high" symptom score alone is not a sufficient 
indication  for  medical  therapy.  The  symptoms  should  be  sufficiently  bothersome  that  the 
patient is willing to make a lifetime commitment to medical therapy, providing the drug is 
effective and adverse experiences are nonexistent or minimal.
            Medical  therapy should not  be offered to individuals  presenting with absolute 
indications for intervention. Individuals presenting with recurrent urinary retention, recurrent 
urinary tract infections, renal insufficiency, bladder calculi, and recurrent gross hematuria may 
develop life-threatening consequences from their BPH if it is not managed surgically. 
            Until  properly  controlled  clinical  studies  unequivocally  demonstrate  favorable 
outcomes, patients presenting with absolute indications should be discouraged from selecting 
medical therapy. If informed patients are willing to accept potential risks, medical therapy may 
be offered with a proviso for careful follow-up and future prostatectomy if medical therapy 
proves ineffective.
PREVENTING BPH WITH MEDICAL THERAPY 
A potential  role  of  medical  therapy  is  to  prevent  the  development  of  BPH  or  its 
progression.  There  are  numerous  factors  limiting  the  enthusiasm  for  preventing  the 
development  of  BPH.  The  clinical  manifestations  of  BPH  are  rarely  life  threatening. 
Preventative intervention would have to be initiated before the fifth decade of life coinciding 
with the development of BPH (Partin, 2000). The long-term exposure to drug-induced adverse 
events and the prohibitive costs are the primary limitations of prevention therapy. In addition, 
effective  medical  and surgical  therapy exists  when BPH ultimately does  become clinically 
evident.
            Because there is no clinical, biochemical, or genetic predictors of BPH development or  
progression, every male is at risk. The ability to identify those individuals who are predisposed 
to  develop  clinical  BPH refractory  to  medical  therapy  would  provide  a  more  compelling 
rationale for prophylaxis. There is evidence that men with very large prostates are at greater  
risk  for  developing urinary  retention  (Jacobsen et  al,  1997)  [15]  and that  medical  therapy 
(finasteride) can significantly decrease this risk of developing urinary retention (McConnell et 
al, 1998). The decision to offer preventative therapy for urinary retention depends on the risk of 
the events, cost associated with treatment, and patient preferences for intervention. [16]
RATIONALE FOR USING α -ADRENERGIC BLOCKERS
The  rationale  for  α-adrenergic  blockers  in  the  treatment  of  BPH  is  based  on  the 
hypothesis  that  the  pathophysiology  of  clinical  BPH is  in  part  caused  by  BOO,  which  is 
mediated by α1 adrenoceptors (α1 AR) associated with prostatic smooth muscle (Caine, 1986). 
The  importance  of  this  dynamic  obstruction  was  supported  by  morphometric  studies 
demonstrating  that  smooth  muscle  is  one  of  the  dominant  cellular  constituents  of  BPH, 
accounting for 40% of the area density of the hyperplastic prostate (Shapiro et al, 1992).
 Caine and coworkers (1975) reported that the human prostate contracts in the presence 
of  the  α-adrenergic  agonist  norepinephrine.[17]  Several  investigators  subsequently 
demonstrated that the tension of prostate smooth muscle is mediated by the α1 AR (Hieble et 
al,  1985;  Lepor  et  al,  1988;  Gup  et  al,  1989).  Lepor  and  Shapiro  (1984)  were  the  first 
investigators to characterize the α1 AR in the human prostate using radioligand binding studies. 
These investigators subsequently reported that 98% of the α1 ARs are localized to the prostatic 
stroma (Kobayashi et al, 1993). The importance of the adrenergic innervation of the prostate 
was further supported by the observation of high levels of norepinephrine in the human prostate 
(Lepor et al, 1990).
            Although the finding of high levels of smooth muscle α1 ARs and norepinephrine in the 
human prostate suggests an important role of the adrenergic innervation in prostatic function, it 
cannot be assumed that these factors are 
directly  responsible  for  clinical  BPH.  Lepor  and  associates  (1990)  reported  no  significant 
differences  between  norepinephrine  levels,  α1  AR density  (Gup  et  al,  1989),  or  isometric 
contractile responses to phenylephrine (Gup et al, 1989) in BPH tissues obtained from men 
with symptomatic and asymptomatic BPH. Other investigators have shown α1 AR levels are 
higher in prostatic adenoma relative to prostatic capsule (Yamada et al, 1987; Kawabe et al,  
1990). 
            These observations simply show regional differences of α1 AR receptors in the prostate 
and do not prove that clinical BPH is caused by up-regulation of the α1 AR.The most definitive 
evidence that blockade of prostate α1 AR relieves BOO was the observed direct relationship 
between the area density of prostate smooth muscle and the change in the PFR in 26 subjects  
undergoing prostatic biopsy before initiating α-blocker therapy with terazosin (Shapiro et al, 
1992). 
            Although the prostates of those subjects achieving symptom improvement had a  
significantly greater group mean area density of smooth muscle compared with those of non 
responders, a direct relationship between prostate smooth muscle area density and change in 
symptom  scores  was  not  observed.  These  observations  suggest  that  non  prostate  smooth 
muscle–mediated α1 AR events may also be responsible for the effectiveness of α blockade and 
that  α1-mediated  symptom improvement  and  decreases  in  BOO are  mediated  by  different 
mechanisms.
CLASSIFICATION OF ΑLPHA ADRENERGIC BLOCKERS
α-Adrenergic  blockers  may  be  classified  according  to  α  AR  selectivity  and  serum 
elimination half-life.  Phenoxybenzamine, a nonselective α blocker,  was shown to be highly 
effective for BPH (Caine et al, 1976, 1978). [17]The limitation of phenoxybenzamine was the 
high incidence and severity of adverse clinical events.
            Berthelson and Pettinger (1977) described two subtypes of  α AR (α1 and α2). Prazosin 
was one of the first α1 AR antagonists to be investigated for the treatment of BPH (Hedlund et 
al, 1983). The efficacy of phenoxybenzamine and prazosin are comparable; however, prazosin 
is better tolerated, implying that efficacy and toxicity are mediated primarily by the α1 AR and 
α2 AR, respectively (Lepor, 1989). Prazosin and other α1 antagonists, including intermediate-
release (IR) alfuzosin (Jardin et al, 1991) and indoramin (Ramsay et al, 1985), require at least 
twice-daily dosing, owing to the relatively short serum elimination half-lives.
            The next advance in the development of α blockers was the development of drugs with 
serum elimination half-lives that allowed for once-a-day dosing. Terazosin (Lepor et al, 1992) 
and doxazosin (Gillenwater et al, 1995) are long-acting α blockers that have been shown to be  
safe and effective for the treatment of BPH.
            Molecular cloning studies have identified three subtypes of the α1 AR (Andersson et al, 
1997).  Price  and  coworkers  (1993)  reported  that  the  mRNA  encoding  the  α1a  AR  is 
predominant in the human prostate. The fact that the α1a mRNA is translated does not mean the 
encoded  protein  is  translated.  Lepor  and  associates  reported  that  using  autoradiographic 
(Kobayashi et al, 1993) and immunohistochemical (Walden et al, 1997) techniques, the α1a AR 
and  α1b  AR  are  predominant  in  the  human  stroma  and  epithelium,  respectively.  Prostate 
smooth muscle tension has been shown to be mediated by the α1a AR (Forray et al, 1994a and 
b). 
            This observation is consistent with the localization of the α1L AR to prostatic stroma. 
Muramatsu and colleagues (1994) subsequently reported that the α1L AR was present in the 
prostate and mediated prostate smooth muscle contraction. The overwhelming evidence to date 
suggests that the α1L AR binding site is a conformational state of the α1a AR (Andersson et al, 
1997).
            Tamsulosin is a once-daily administered α1 antagonist that exhibits some modest degree  
of selectivity for the α1a versus the α1b AR and no selectivity for the α1a versus the α1d AR 
(Foglar Of all of the other factors examined only the post void residual volume (PVR) after a 
successful TWOC approached statistical significance, those with residuals of > 50 ml being 
more  likely  to  fail  during  the  follow-up.  The  pharmaceutical  industry  has  developed  α1 
antagonists that are 1000-fold selective for the α1a AR versus α1b/α1d (Forray et al, 1994b). 
Because the α1 AR subtypes mediating efficacy and adverse effects are unknown, the optimal 
specific α1 AR subtype antagonist for the treatment of BPH cannot be predicted (Lepor, 1996). 
The clinical use of these highly selective α1AR antagonists will be defined by future clinical 
trials.
ALFUZOSIN 
IR alfuzosin was investigated for the treatment of BPH primarily in Europe in the early 
1990s.  Jardin and colleagues (1991) reported the  first  large-scale,  multicenter,  randomized, 
placebo-controlled trial demonstrating that alfuzosin was safe and effective for the treatment of 
BPH. A long-term open-label extension study showed that the effectiveness of alfuzosin was 
durable up to 30 months (Jardin et al, 1994). The primary limitation of IR alfuzosin was a 
requirement for multiple daily doses (2.5 mg three times a day or 5 mg twice a day). In the 
absence of any demonstrable advantage over the once-a-day drugs like terazosin, doxazosin, 
and tamsulosin, there was no compelling reason to prescribe IR alfuzosin.
            
SR ALFUZOSIN
SR alfuzosin is a new formulation that allows for a once-daily dosing regimen without 
dose  titration.  SR  alfuzosin  is  not  currently  registered  in  the  United  States.  Buzelin  and 
coworkers (1997) reported the first randomized, multicenter, placebo-controlled trial evaluating 
the safety and effectiveness of SR alfuzosin for the treatment of  BPH. Three hundred and 
ninety subjects were randomized to once-daily 5 mg alfuzosin versus placebo for 12 weeks. 
The treatment-related improvements in the IPSS and PFR were -1.6 symptom unit  and 1.3 
ml/sec, respectively. The incidence of dropouts because of adverse events was 4.6% and 7.1% 
in the SR alfuzosin and placebo groups, respectively. The 2-mm Hg change in systolic and 
diastolic blood pressure was not significantly different from that in the placebo group. The 
incidences of dizziness and asthenia were similar in the SR alfuzosin and placebo groups.
            SR alfuzosin (10 mg once a day) has been compared with IR alfuzosin (2.5 mg three  
times daily) and placebo (van Kerrenbroeck et al, 2000). After a 1-month placebo lead-in, 447 
patients  were  randomly  assigned  in  equal  proportions  to  the  three  treatment  groups  for  3 
months.  The  improvement  in  the  IPSS was  6.9,  6.4,  and 4.9  in  the  alfuzosin  10  mg/day, 
alfuzosin  2.5  mg  three  times  a  day,  and  placebo  groups,  respectively.  The  symptom 
improvement observed in both active treatment groups was significantly greater than that in the 
placebo group. The improvements in the filling and voiding subscores and quality of life index 
were also significantly greater in the active treatment group relative to the placebo group. 
The improvement in the PFR was 2.3 ml/sec,  3.2 ml/sec,  and 1.4 ml/sec in the SR 
alfuzosin, IR alfuzosin, and placebo groups, respectively. The modest improvements in the PFR 
were  significantly  greater  in  both  active  treatment  groups  compared  with  placebo.  The 
incidences of dizziness were 2.1%, 4.7%, and 1.3%; and those for asthenia were 3.5%, 0.7%, 
and 2.6% in the SR alfuzosin, IR alfuzosin, and placebo groups, respectively. 
            No sexual dysfunction was reported in the 10-mg/day alfuzosin group. There were no 
statistically or clinically significant treatment-related effects on blood pressure in normotensive 
or hypertensive subjects. Of those men who were hypertensive at baseline, the mean reductions 
in the standing blood pressure were 8.1, 8.6, and 5.8 mm Hg, respectively, in the SR alfuzosin,  
IR alfuzosin, and placebo groups. The lack of adverse events and meaningful blood pressure 
effects appears to be the distinguishing characteristic of SR alfuzosin compared with terazosin 
and doxazosin.
            Because of the lack of adverse effects and blood pressure changes, alfuzosin has been  
promoted as  an  uroselective  drug  (Kirby,  1998a).  SR alfuzosin  exhibits  no  pharmacologic 
uroselectivity  for  any  of  the  α1  subtypes  (Andersson  et  al,  1997).  In  vivo  studies  in  the 
conscious rat have shown that alfuzosin reduces urethral pressure without significantly altering 
blood pressure  (Martin  et  al,  1995).  This  experimental  observation does  not  prove clinical 
uroselectivity  because terazosin and doxazosin do not alter blood pressure in normotensive 
subjects. Another explanation for the lack of adverse events has been the low penetration of 
alfuzosin into the brain (Rouguier et al, 1994). 
            It is also important to consider that the better tolerance may simply be related to a lower 
level of α1 blockade because the treatment-related improvement of the 10 mg of alfuzosin 
appears to be less than that achieved with 10 mg of terazosin and 8 mg of doxazosin.
            The long-term effectiveness of IR alfuzosin 2.5 mg three times a day is supported by an  
open-label prospective 3-year trial involving 3228 men with clinical BPH (Lukacs et al, 2000). 
The  improvements  in  symptom  score  in  BPH-specific  health-related  quality  of  life  index 
observed at the 3-month visit were maintained throughout the 36 months of follow-up. A total 
of 20.1% of the men withdrew from the study. Only 4.2% of the men discontinued therapy 
because  of  an  adverse  event.  The  other  reasons  for  withdrawal  were  death,  7.6%;  loss  of 
follow-up, 1.7%; lack of efficacy, 1.8%; study withdrawal owing to personal reasons, 0.8%; 
concomitant disease,  0.7%; and other  reasons,  3.3%. Only 0.3% of men experienced acute 
urinary retention. It is reasonable to assume that the SR alfuzosin also exhibits durability of 
effectiveness.
EFFECTS OF ΑLPHA BLOCKERS ON BOO
The  primary  objective  of  medical  therapy  is  to  improve  urinary  symptoms.  The 
relevance of urodynamic studies for assessing the clinical use of medical therapy for BPH is 
controversial. A drug that improves urodynamic parameters of BOO without relieving LUTS 
would be of limited clinical utility. Conversely, a drug that relieves LUTS without improving 
urodynamic parameters of BOO would be of great clinical importance. There are relatively few 
randomized, placebo-controlled studies examining the effects of α blockers on pressure-flow 
parameters. One of the limitations to designing these urodynamic studies is the definition of a 
clinically significant outcome.
Martorana  and  colleagues  (1997)  reported  a  randomized,  double-blind,  placebo-
controlled study examining the effect of 1 month of alfuzosin, 2.5 mg three times a day, on 
pressure-flow urodynamic parameters.  The changes  in  detrusor  pressure  at  maximum flow, 
detrusor opening pressure, and maximum detrusor pressure were significantly greater in the 
alfuzosin-treatment  group  compared  with  the  placebo  group.  There  were  no  significant 
differences between the effects of alfuzosin and those of placebo on PFR.
SR ALFUZOSIN IN ACUTE URINARY RETENTION 
It is reasonable to speculate that urinary retention is caused in part by dynamic factors 
because a significant proportion of men void spontaneously after catheter placement (Taube 
and Gajraj, 1989). If urinary retention is caused by increased sympathetic activity at the level of 
the  prostatic  smooth  muscle,  an  α  blocker  should  increase  the  likelihood  of  spontaneous 
voiding after catheter removal. [4] 
The  advantage  of  SR alfuzosin  and tamsulosin  over  terazosin  and doxazosin  in  the 
management of acute urinary retention is that a therapeutic dose can be administered at the 
onset of treatment, thereby decreasing the time for attempting catheter removal.
            A large-scale, randomized, double-blind, placebo-controlled, trial of long-term duration 
is required to determine whether a medical therapy prevents urinary retention. Unfortunately, 
no randomized, double-blind, placebo-controlled studies of α blockers exceed 1 year of active 
treatment.  Because men with large prostates have a threefold greater chance of developing 
urinary retention (Jacobsen et al, 1997), enrolling men with large prostates would enhance the 
probability of observing an effect on urinary retention. The 3-year open-label prospective study 
of alfuzosin supported a 0.3% risk of retention (Lukacs et al, 2000). This is markedly lower 
than  the  predicted  risk  of  developing  urinary  retention  in  an  age-matched  cohort  of  men 
(Jacobsen et al, 1997). [15]
            The MTOPS study is a 7-year placebo-controlled trial of 2800 men designed to  
determine  the  impact  of  medical  therapy (placebo,  doxazosin  alone,  finasteride  alone,  and 
combination  therapy)  on  disease  progression.  This  study  will  determine  the  impact  of  α 
blockers on preventing urinary retention.
ADVERSE EVENTS WITH ALPHA BLOCKERS
Dizziness and asthenia are the adverse events most commonly associated with α blocker 
therapy.  Elucidating  the  mechanism of  action  for  these  adverse  events  is  essential  for  α1 
subtype drug development programs. It has been assumed that dizziness and possibly asthenia 
were caused by cardiovascular effects. Lepor and colleagues (2000) correlated the incidence of 
adverse events associated with terazosin relative to blood pressure changes. Men experiencing 
dizziness and asthenia did not exhibit greater changes in blood pressure while on terazosin 
therapy. Only postural hypo tension was associated with greater changes in blood pressure. 
            Alpha 1-Adrenergic–mediated dizziness and asthenia are likely due to effects at the 
level of the CNS. Therefore, it cannot be assumed that developing an α blocker that eliminates  
effects on blood pressure will significantly improve the tolerability of α blockers. 
COMPARISON OF ΑLPHA ADRENERGIC BLOCKERS 
Buzelin  and  coworkers  (1997a)  reported  a  randomized,  placebo-controlled  study 
comparing α blockers (IR alfuzosin, 2.5 mg three times a day, versus tamsulosin, 0.4 mg/day).  
The improvements in Boyarsky symptom score and PFR and the incidences of dizziness and 
asthenia  were  not  significantly  different  between the  two treatment  groups.  The  effects  of 
alfuzosin and tamsulosin on systolic and diastolic supine or standing blood pressures in the 
hypertensive patients were also not significantly different. This study suggests that IR alfuzosin 
and  tamsulosin  have  equivalent  effectiveness  and  tolerability.  The  obvious  benefit  of 
tamsulosin is that the dose does not have to be titrated.
            The recommended daily doses of terazosin, doxazosin, tamsulosin, and SR alfuzosin are  
10 mg, 8 mg, 0.4 mg, and 10 mg, respectively. The clinical data suggest that terazosin, 10 mg,  
and doxazosin, 8 mg, are more effective than tamsulosin, 0.4 mg, and alfuzosin, 10 mg. The 
incidences  of  asthenia  and dizziness  appear  to  be  higher  for  terazosin and doxazosin.  The 
apparent better tolerability of tamsulosin and SR alfuzosin may simply be because of degree of 
α1 blockade and not uroselectivity.
            Terazosin and doxazosin exhibit very similar pharmacological and pharmacokinetic  
properties. It is, therefore, not surprising that the effectiveness and tolerability of these two 
agents  are  also  comparable.  The  effectiveness  of  terazosin  and  doxazosin  are  both  dose 
dependent, with the greatest recorded improvements in symptom scores observed at the 10-mg 
and 8-mg daily doses, respectively. These doses have both been shown to be significantly more 
effective than lower doses. Although the incidence of adverse events is dose dependent, the 10-
mg and 8-mg doses of terazosin and doxazosin are generally well tolerated.
            Tamsulosin and SR alfuzosin have been positioned as uroselective α1 blockers. One of 
the assumed advantages of a uroselective α1 blocker is better tolerance. Whereas the 0.8-mg 
tamsulosin dose appears to have less asthenia than terazosin and doxazosin, the incidence of 
dizziness  is  comparable  and  rhinitis  and  abnormal  ejaculation  are  markedly  greater. 
Tamsulosin,  0.4  mg,  is  the  only  reasonable  dose,  owing  to  the  cost  and  adverse  events 
associated with the 0.8-mg dose. 
            The major advantage of 0.4 mg of tamsulosin and SR alfuzosin is  the lack of  
requirement for  dose titration.  For men presenting in  urinary retention,  tamsulosin and SR 
alfuzosin will likely decrease the time to voiding trial because of the lack of titration to an 
effective dose. The data suggest that tamsulosin and SR alfuzosin exhibit less effect on blood 
pressure in hypertensive men compared with terazosin and doxazosin. The fact that terazosin 
and  doxazosin  lower  blood  pressure  in  men  who  are  hypertensive  may  be  an  advantage, 
especially because 30% of men with BPH have hypertension.
TWOC AND ALFUZOCIN
Acute urinary retention (AUR) is the presenting feature in 23–27% of men undergoing 
prostatectomy  for  benign  conditions.  The  increased  perioperative  mortality  and  morbidity 
observed in this group are in part due to an increased risk of sepsis and bleeding associated 
with urinary catheterization before surgery. It is therefore preferable that patients do not have 
urinary catheters at the time of prostatic surgery, and hence it is common practice for a patient  
to undergo a trial without catheter (TWOC).  The success rate of this TWOC is reportedly 23–
28%, with 35% of those who are successful requiring prostatic surgery within 6 months
            If urinary retention is caused by increased sympathetic activity at the level of the  
prostatic smooth muscle, an α blocker should increase the likelihood of spontaneous voiding 
after catheter removal. McNeill and coworkers (1999) examined the effects of SR alfuzosin, 5 
mg twice a day, versus placebo in men presenting with acute urinary retention. The indwelling 
urinary catheter was removed 24 hours after initiation of treatment. Men were excluded if the 
bladder volume at the time of catheter drainage was greater than 1.5 liters. Fifty-five percent 
and 29% of men randomized to the SR alfuzosin and placebo groups voided spontaneously 
after catheter removal, respectively. The clinical effect was greatest in younger men. Of the 
men  who  successfully  completed  the  voiding  trial,  32%  ultimately  experienced  a  second 
episode of acute urinary retention or underwent prostatectomy. [36,40]
            The advantage of SR alfuzosin and tamsulosin over terazosin and doxazosin in the  
management of acute urinary retention is that a therapeutic dose can be administered at the 
onset of treatment, thereby decreasing the time for attempting catheter removal. 
           Alfuzosin is a selective alpha1-adrenoceptor antagonist shown to have functional  
uroselectivity.  It  effectively  relieves  LUTS related  to  BPO and  the  sustained-release  (SR) 
formulation has been shown to have a urodynamic effect within 3 hours of first administration. 
Its good safety profile and rapid onset of action make it appropriate for use before a TWOC 
following AUR. There is now good evidence that giving the α-blocker alfuzosin to men with 
benign prostatic obstruction (BPO) before a trial without catheter (TWOC), after a first episode 
of acute urinary retention (AUR), significantly improves the chances of a successful return to 
voiding.
                                   PATIENTS AND METHODS
Between December 2004 and October 2006, 120 men aged 52–83 years (mean 64.3) 
presented with AUR related to Benign Prostatic Hyperplasia and a residual urine volume of 
0.5–1.5 L on catheterization were enrolled in a prospective, randomized, double-blind, placebo-
controlled study, and randomly assigned to receive SR alfuzosin 10mg once daily (60 patients) 
or placebo (60 patients): the intent-to-treat (ITT) population was 120 patients. All had been 
admitted to hospital through the Accident and Emergency Department with AUR, and had been 
catheterized in the previous 72 hours.
                                                           AGE GROUPS
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            After catheterization the drained volume of urine (residual volume of AUR), size of 
prostate (assessed by a DRE & abdominal USG) and study number were recorded on a standard 
case-report form. As a TRUS estimate of prostate size was not available for this study the 
admitting urologist was asked to categorize the prostate as small (≤20 g), medium (21–50 g) or 
large (≥51 g). Serum was sent for assay of serum creatinine, and urine routine examination was 
done  and  a  sample  sent  for  urine  culture.  The  time  and  date  of  commencement  of  trial 
medication and catheter removal were also recorded. 
            Men with initial catheterization volumes of >1500 ml or <500 ml were excluded. Other 
exclusion criteria are evidence of renal or hepatic dysfunction; previous surgery on the urinary 
tract; other diseases of the bladder; any malignancy; retention-enhancing medications; allergies; 
and severe cardiac disease. The exclusion criteria are listed separately in the next page.     
            Full informed written consent was sought from eligible patients. Those who gave  
consent were randomly allocated to receive either SR alfuzosin (10 mg once daily, with no dose 
titration) or placebo once daily for 7 days (7 doses).. The catheter was removed after 24 h of the 
full course of medication. We packaged the SR alfuzosin and placebo to appear identical and 
each batch of seven tablets was allocated a study number generated randomly by computer. A 
sealed copy of the code was held by the investigator.
SUCCESS
In the  absence of any internationally  agreed outcome measures  for  the success  of a 
TWOC,  TWOC  was  considered  successful  if  the  patient  returned  to  satisfactory  voiding 
(defined as  a  flow rate  of  >  5 ml/s,  >125 ml  voided volume,  and a  residual  volume of  ≤ 
250 ml).  These  definitions  are  regarded  as  a  reasonable  reflection  of  successful  bladder 
emptying; and deemed a failure if re-catheterization was required within 24 hours.
FOLLOW-UP 
The  patients  were  then  followed  to  the  time  of  prostatic  surgery  for  some  other 
indication  other  than  AUR  or  re-catheterization  due  to  recurrent  AUR  while  those  who 
continued to void remained under open follow-up. The failures during follow-up of patients 
who had a  successful  TWOC were defined as  a  subsequent  occurrence of  AUR and/or  of 
bladder outlet surgery.
EXCLUSION CRITERIA:
 Patients unwilling to give informed consent.
 Significant renal and/or hepatic disease; depressive illness on medication;
 Neurological  diseases,  e.g.  multiple  sclerosis,  spinal  injury;  confirmed  or  suspected 
urethral stricture.
 UTI, acute or chronic prostatitis.
 History of prostatic or bladder neck surgery.
 Carcinoma of the prostate suspected or confirmed.
 History of unstable angina pectoris, myocardial infarction, transient ischaemic attacks, 
Cerebrovascular accident or congestive cardiac failure during the previous 6 months; 
Current  or  previous  orthostatic  hypotension  (decrease  of  >  20 mmHg of  systolic  or 
diastolic blood pressure).
 Patients  taking  monoamine  oxidase  inhibitors,  cholinergic  or  anticholinergic  drugs, 
calcium-channel blockers, or α-blocking drugs. Other antihypertensive drugs not to be 
altered whilst the patient receives the trial medication.
 Known hypersensitivity to alfuzosin or α-blockers.
 Patients  requiring  suprapubic  catheterization  where  urethral  catheterization  was 
unsuccessful.
 Retention after major abdominal/pelvic surgery.
 Large PVR (>1.5 L).
 Clot retention secondary to haematuria of any cause.
PATIENT  PROFORMA
1. Name:
2. Serial Number:
3. Age:
4. Urine volume after Catheterization:
5. Prostate Size on DRE & USG:
6. Investigations:
            Urine routine:
            Urine Culture:
            Sr.Creatinine :
7. Date of starting first dose:
8. Adverse Effects:
9. TWOC (Success/Failure):
10. PVR if voided successfully:
11. Follow-up Duration:
12. Follow-up Result:
OBSERVATION AND RESULTS
Of the 120 patients recruited, 60 received SR alfuzosin and 60 placebo. All variables 
like patient age, prostate size and residual volume of AUR were comparable in both treatment 
groups.  Two  patients  in  each  group  gave  a  history  of  constipation,  which  was  treated 
appropriately and was not found to influence the outcome.
            After removing the catheter, voiding was successful in 28 of the 60 patients (47%)  
receiving SR alfuzosin and in 15 of the 60 patients (25%) receiving placebo, the difference 
being statistically significant (P=0.014).  This translates into an odds ratio of 2.63 (95% CI 
1.13–6.24).Remaining patients were either not able to pass urine satisfactorily or required re-
catheterization within 24 hours.
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               Comparing the recorded variables between those who had a successful TWOC and 
those who did not, regardless of treatment group, revealed that age significantly influenced the 
outcome. Those who had a successful TWOC were a mean of 5.5 years younger than those who 
failed to void (P=0.015). The difference in favour of younger patients was more pronounced 
within the placebo group.
              
                 
                                                   
           
         
           The volume of urine after initial catheterization (Residual volume of AUR) has been 
reported to  affect  the chances  of  a successful  return to  voiding.  22 cases out  of  38 in  the 
 
Alfuzocin group and 10 out of 34 in the placebo group with residual volume of AUR <900 ml 
successfully voided in TWOC. But only 6 cases out of 22 in the Alfuzocin group and 5 cases 
out of 26 in the placebo group with urine volume after initial catheterization >900 ml were 
successful in TWOC.This translate into odds ratio of 2.69 (95% CI 1.14 - 6.64) and P value is  
0.02 which is statistically significant. Patients with residual volumes of >1.5 L were excluded 
from the present study.
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There was no difference in outcome that could be related to prostate size in the present 
study,  possibly  because  prostate  size  was  assessed  by  a  DRE  &  abdominal  USG  in  the 
emergency context,  which is much less reliable than TRUS. Number of successful cases in 
relation to prostate  size  is  given in the  table below. Here  the  P value is  0.72 and so it  is  
statistically insignificant
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                 Postvoid residual volume (PVR) was assessed by ultrasonography for those who had 
a  successful  TWOC.  Among  those  43  patients  who  voided  successfully,  6  cases  in  the 
Alfuzocin group & 4 in the placebo group had PVR    > 150 ml. Remaining 33 patients had 
PVR <150 ml. There was no correlation between the residual volume of the AUR and the PVR 
after a successful TWOC.
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            Elderly patients (70 years or older) and patients with a drained volume of 900 ml or 
greater had significantly greater chances of TWOC failure. Nevertheless, even in the presence 
of  these  2 factors  10 mg alfuzosin once daily  almost  doubled the  likelihood of  successful 
TWOC. . No other factors were significantly different between the outcome groups.
 ADVERSE EVENTS
Alfuzosin (10  mg) once daily  was well  tolerated.  Four patients  in  the  SR alfuzosin 
treatment  group experienced adverse  events,  while  no adverse  events  were  reported in  the 
placebo group. Three patients experienced dizziness and one developed a headache, and all 
resolved with no treatment. None interfered with the continuation of the study.
RESULTS OF FOLLOW-UP
The failures during follow-up of the 43 patients  who had a successful  TWOC were 
defined as a subsequent occurrence of AUR and/or of bladder outlet surgery. Among the 43 
patients who had a successful TWOC, six failed to attend their follow-up appointment. For the 
other 37 patients the mean (range) follow-up was 7.6 months (3 days–13 months). 16 patients 
experienced subsequent episodes of AUR or have undergone prostatectomy (TURP) with a 
mean interval from discharge after the successful TWOC of 4.2 months (range 3 days to 8.5  
months).  Two died at 5 and 9.5 months of follow-up for some other causes with no further  
intervention.   Overall,  19  patients  (44%)  have  had  no  subsequent  episodes  of  AUR  and 
continue to void satisfactorily.
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11  out  of  24  successful  cases  in  the  Alfuzocin  group  on  follow-up  subsequently 
developed AUR or underwent TURP. 5 cases out of 13 in the placebo group went for recurrent 
AUR or TURP. Here the P value is 0.66 and Odds ratio is 1.35 (95% C.I 0.28-6.69) which is 
statistically not significant.  So,  initial doses of Alfuzocin may not be helpful in preventing 
subsequent failure.
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                Elderly patients (65 years or older) had significantly greater chances of subsequent 
failure (recurrent AUR or Surgery). 7 out of 24 successful cases in <65 years group & 9 out of  
13 cases in >65 years age group developed recurrent AUR or required surgery for BPH during 
follow-up.  Here P value is  0.019 which translates into Odds ratio of 5.46 (95% CI 1.03 – 
31.71). So the relation between the age and subsequent failure is statistically significant. 
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Post void residual volume (PVR) was assessed by ultrasonography for those who had a 
successful TWOC. Six of eight patients who had a PVR of >150 ml required outflow tract 
surgery(TURP) or developed subsequent AUR  and Ten of 29 patients who had a PVR of <150 
ml have required bladder outlet surgery or developed further episode of AUR, the difference 
being statistically significant (P value is 0.03). This translates into an odds ratio of 0.16 (95% 
CI 0.02–1.14).
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                                             P Value – 0.03     Odds ratio – 0.16
               No other factors were identified to date as being prognostic of the subsequent need for 
TURP. Prostate size categorized as small (≤20 g), medium (21–50 g) or large (≥51 g) on a DRE 
and  abdominal  USG  by  the  admitting  urologist  was  not  associated  with  a  statistically 
significant trend. (P value 0.98) 
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Of all of the other factors examined only the post void residual volume (PVR) after a 
successful TWOC and advanced age (>65 years) approached statistical significance, those with 
above 65 years & residuals of >150 ml being more likely to fail during the follow-up.
DISCUSSION
Historically, the standard management of a man presenting with AUR caused by BPH 
was early prostatectomy, as it was assumed that the patient was presenting late in the natural 
history  of  their  BOO.  However,  a  study  reporting  the  urodynamic  assessment  of  men 
presenting with AUR showed that up to 23% did not require prostatectomy . Furthermore, it is  
recognized that patients undergoing TURP with a urinary catheter insitu are at a greater risk of 
peri- and postoperative complications.  
           Therefore it is common practice to undertake a TWOC after an episode of AUR. As  
previously reported, the success rate of this TWOC is significantly improved by giving an α-
blocker such as alfuzosin . By examining the fate of a cohort of men who have had a successful  
TWOC it is possible to assess whether the AUR event is indeed the culmination of a slow 
decline associated with BPO. 
           An alternative hypothesis is that AUR is truly an acute event, of uncertain cause, 
associated  with  a  sudden  decompensation  of  the  detrusor  or  increase  in  bladder  outlet 
resistance.  This  being  so  it  is  possible  that  α-blockers  and  a  period  of  catheter  drainage,  
allowing inflammation to settle, would improve the outcome of a TWOC. Available evidence 
seems to support both hypotheses, indicating that several different causal factors may result in 
the development of AUR
           The primary objective of the present study was to evaluate the efficacy of Alfuzocin 
compared  with  placebo  for  treating  catheterized  patients  with  AUR  caused  by  BPH,  by 
comparing those voiding successfully after removing their catheter. The definition of ‘success’ 
in the treatment of AUR has yet to be universally agreed. For patients it must, at least in part, 
relate to the lack of need for re-catheterization.                   
           In the absence of any internationally agreed outcome measures for the success of a 
TWOC, TWOC  was  considered  successful  if  the  patient  returned  to  satisfactory  voiding 
(defined as  a  flow rate  of  >  5 ml/s,  >125 ml  voided volume,  and a  residual  volume of  ≤ 
250 ml).  These  definitions  are  regarded  as  a  reasonable  reflection  of  successful  bladder 
emptying; and deemed a failure if re-catheterization was required within 24 hours. This criteria 
is used in 2 similar studies. (Malcolm G. Lucas et al)[10]
           This study shows that patients receiving SR alfuzosin were about two times more likely 
to  void  successfully  than  those  who  received  placebo.  The  success  rate  of  TWOC in  the 
placebo  group  of  25%  is  of  the  same  order  of  magnitude  as  that  reported  in  previous 
uncontrolled  observational  studies.  SR  alfuzosin  gave  a  significantly  better  outcome  than 
placebo. 28 patients who received SR alfuzosin and 15 who received placebo did not require 
re-catheterization (47% vs. 25% success, P = 0.011; odds ratio 2.47, 95% CI 1.23–4.97).
           Similar study by  McNeill SA, Daruwala PD, Mitchell IDC, Shearer MG, Hargreave TB. 
Sustained-release  alfuzosin  and  trial  without  catheter  after  acute  urinary  retention:  a 
prospective, placebo-controlled trial. BJU Int 1999; 84: 622–7 In this study after removal of the 
catheter, 42% of patients voided successfully, 22 of 40 (55%) with SR alfuzosin and 12 of 41 
(29%) with placebo (P=0.03). [40]
           Tamsulosin in the management of patients in acute urinary retention from benign 
prostatic  hyperplasia,  a  study  conducted  by  Malcolm  G.  Lucas  et  al  published  in  BJU 
International  Volume  95  Page  354   -  February  2005.In  that  study  149  men  (mean  age 
69.4 years) were randomly assigned to receive tamsulosin (75) or placebo (74); eight were not 
evaluable, so the intent-to-treat population was 141 men. Thirty-four men taking tamsulosin 
and 18 taking placebo did not require re-catheterization on the day of the trial without catheter  
(48% and 26% respectively,  P = 0.011; odds ratio 2.47, 95% confidence interval, CI, 1.23–
4.97) [10]
In  the  present  study  it  was  apparent  that  increasing  age  was  associated  with  less  
likelihood of a successful TWOC; indeed, no patient over 80 years old voided successfully. 
This  finding reflects  recent reports  that  increasing age is  a  risk factor  for  AUR, failure  of  
TWOC after AUR and poor outcome after surgery. This risk of AUR and poor outcome of  
TWOC and surgery with increasing age may be related to the increasing incidence of prostatic 
obstruction associated with ageing and the age-related decline in detrusor contractility.
            The size of the residual volume after AUR has been reported to affect the chances of a  
successful return to voiding. According to Taube and Gajraj, a TWOC should be avoided if the  
residual volume is  >900 ml.  [4] Similarly,Djavan et  al.  found that  a residual of <1 L was 
associated with a good chance of successful voiding after catheter removal, but recommended a 
period of prolonged catheterization if the volume was >1.3 L. [34]
           In our study totally 32 cases out of 72 (44%) in both groups with urine volume of initial  
catheterization (Residual volume of AUR) <900ml voided successfully.  But only 11 out of 
48(23%) cases with initial catheterization volume >900ml had success in TWOC (P value-0.02, 
odds ratio 2.69).The Residual volume of AUR affect the outcome in our study similar to other  
studies. But McNeil in his study found the residual volume had no effect on the outcome of the 
TWOC.[5]
           Prostate size has also been identified as a risk factor for urinary retention and thus may  
be a useful indicator of outcome after retention. Kumar V, Marr C, Bhuvangiri A, Irwin P. A 
prospective study of conservatively managed acute urinary retention: prostate size matters. BJU 
Int 2000; 86: 816–9 shows prostate size affecting the success rate, but they assess the size by 
means of TRUS. There was no difference in outcome that could be related to prostate size in  
the present study, possibly because prostate size was assessed by a DRE & abdominal USG in 
the emergency context, which is much less reliable than TRUS.[21]
           The follow-up data revealed that 19 out of 37 of those who voided successfully (51%) 
required no further intervention within a mean follow-up of 7.2 months after an episode of 
AUR,  with  16  of  37  (43%)  experiencing  a  further  episode  of  AUR  and/or  requiring  a 
prostatectomy  within this period.  However, it is encouraging that so many patients remained 
free of intervention after a successful TWOC, as this permits time for a full assessment of these 
patients, which in turn may facilitate surgical intervention in the absence of a urinary catheter.
           McNeill SA, Hargreave TB and Members of the Alfaur Study Group. Alfuzosin once 
daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004; 171: 2316–
20 found 14 (17.1%) of the 82 alfuzosin-treated patients versus 20 (24.1%) of the 83 placebo-
treated patients required BPH surgery, 5 (36%) of 14 versus 13 (65%) of 20 within 1 month, 
and 8 (57%) of 14 versus 17 (85%) of 20 within 3 months of treatment. Emergency surgery 
because of AUR relapse was the main cause of failure in both groups (11 [78.6%] of 14 in the  
alfuzosin group and 16 [80.0%] of 20 in the placebo group). [5]
           In their study, compared with placebo, alfuzosin improved the Kaplan-Meier survival 
rates by 9.6% (P = 0.04), 11.4% (P = 0.04), and 8.3% (P = 0.20), with surgical risk reductions 
of 61%, 52%, and 29% at 1, 3, and 6 months of treatment, respectively. High prostate-specific  
antigen values and the post-TWOC residual urine volume significantly increased the risk of 
AUR relapse and BPH surgery. They recommend Alfuzosin 10 mg OD increased the likelihood 
of successful TWOC in men with a first episode of spontaneous AUR and should be continued 
beyond the acute phase, as it reduced the need for BPH surgery during a 6-month treatment  
period.
           But in our study 11 out of 24 successful cases in the Alfuzocin group on follow-up 
subsequently developed AUR or underwent TURP. 5 cases out of 13 in the placebo group went 
for recurrent AUR or TURP. Here the P value is 0.66 and Odds ratio is 1.35 (95% C.I 0.28-
6.69) which is statistically not significant. So, initial doses of Alfuzocin may not be helpful in 
preventing subsequent failure. But we are not putting Alfuzocin in the follow-up period.
           Elderly patients (65 years or older) had significantly greater chances of subsequent 
failure (recurrent AUR or Surgery).7 out of 24 cases in <65 years group & 9 out of 13 cases in  
>65 years age group developed recurrent AUR or required surgery for BPH. . Here P value is 
0.019 which translates into Odds ratio of 5.46 (95% CI 1.03 – 31.71). So the relation between 
the age and subsequent failure is statistically significant. 
           McNeill SA, Rizvi S, Byrne D. Prostate size influences the outcome after presenting 
with acute urinary retention. BJU Int 2004;94: 559–62 In this study, those with larger prostates 
are most at risk of recurrent AUR or surgery after a successful TWOC, just as they are at higher 
risk of developing AUR initially. But in our study Prostate size categorized as small (≤20 g), 
medium (21–50 g)  or  large (≥51 g)  on a DRE & USG by the admitting urologist  was not 
associated with a statistically significant influence on the subsequent failure in the follow-up 
period.( P value = 0.98). [36,40]            
           Post void residual volume (PVR), of those who had a successful TWOC is considered as  
an important prognosticator of subsequent failure in many studies. Six of eight patients who 
had a PVR of >150 ml required outflow tract surgery(TURP) or developed subsequent AUR 
,Ten  of  29  patients  who  had  a  PVR of  <150  ml  have  required  bladder  outlet  surgery  or  
developed further episode of AUR, the difference being statistically significant (P=0.03). 
           Of all of the other factors examined only age and the post void residual volume (PVR) 
after a successful TWOC approached statistical significance, Older age (>65 years) and those 
with residuals of >150 ml being more likely to fail during the follow-up. No other factors were 
identified to date as being prognostic of the subsequent need for TURP.
           The distribution of patients was equal in both study groups, and so is unlikely to have 
affected  the  analysis  of  whether  the  treatment  effects  of  Alfuzocin  differ  from those  of  a 
placebo. The safety profile was as expected for an alpha blocker,  only 4 patients had mild 
dizziness and head ache.
           Many questions remain unanswered about the use of alpha blockers in the clinical 
setting. It is still not possible to predict which patients are likely to respond to a-blockers and 
which are not; the study was not powerful enough to answer this. There were also insufficient 
data to draw conclusions about long-term outcomes for  patients  treated with SR alfuzosin. 
Published data from untreated patients suggested that many will require recatheterization or 
surgical intervention; 84% had surgery within 5 years in one study.
           It would be valuable to study the long-term use of SR alfuzosin after catheterization for  
AUR.  Works  with  another  a-blocker,  Tamsulocin,  shows  that  treatment  for  6  months  was 
associated with a significantly lower incidence of de novo AUR than with placebo (0.4% vs. 
2.4%).  A retrospective  analysis  of  five  studies  of  the  long-term use  of  alpha  blockers  for 
treating BPH showed that the incidence of AUR was significantly lower in patients taking this 
group of drugs, and there was a possible reduction in the need for surgery. From those results, 
SR alfuzosin can also be recommended for treating patients after catheterization for AUR, and 
can significantly reduce the likelihood of the need for re-catheterization.
           A large-scale, randomized, double-blind, placebo-controlled, trial of long-term duration 
is required to determine whether a medical therapy prevents urinary retention. Unfortunately, 
no randomized, double-blind, placebo-controlled studies of α blockers exceed 1 year of active 
treatment.  Because men with large prostates have a threefold greater chance of developing 
urinary retention (Jacobsen et al, 1997), enrolling men with large prostates would enhance the 
probability of observing an effect on urinary retention. The 3-year open-label prospective study 
of alfuzosin supported a 0.3% risk of retention (Lukacs et al, 2000). This is markedly lower 
than  the  predicted  risk  of  developing  urinary  retention  in  an  age-matched  cohort  of  men 
(Jacobsen et al, 1997). [15] 
The  MTOPS  study  is  a  7-year  placebo-controlled  trial  of  2800  men  designed  to 
determine  the  impact  of  medical  therapy (placebo,  doxazosin  alone,  finasteride  alone,  and 
combination  therapy)  on  disease  progression.  This  study  will  determine  the  impact  of  α 
blockers on preventing urinary retention.
                                                      CONCLUSION
In conclusion, this study provides evidence from a randomized double-blind placebo 
controlled trial that an alpha-blocker, SR alfuzosin, is useful in the management of AUR related 
to BPH. This study shows that patients receiving SR alfuzosin were about twice more likely to 
void successfully than those who received placebo. In addition, it provides further evidence that 
the patient age (>70 years) and residual volume of AUR (>900ml) are the factors significantly 
affecting the outcome.
            While treatment with a1pha blockers may not obviate the need for surgery in all men 
who present with AUR, a reduction in the numbers being sent home with urinary catheters in 
situ is of benefit, as it may reduce subsequent perioperative morbidity and mortality, and it is  
more comfortable and convenient for the patients.  
            It is clear that certain measurable parameters like advanced age and large PVR after a  
successful  TWOC (> 150ml)  may be used  to  identify  patients  at  highest  risk of  a  further 
episode  of  AUR after  initial  success  at  TWOC,  who may  then be  offered  early  operative 
intervention. 
                                  
                                          MASTER CHART
AGE PROSTATE 
SIZE
RESIDUAL 
VOLUME 
OF AUR
ALF/PLA SUC/FAIL PVR  IN 
SUCCESSFUL 
PATIENTS
FOLLOW 
UP
FOLLOW 
UP 
RESULT
1 54 medium 600 A S 120 13 Months Voiding
2 67 medium 700 A S 180 2.5 months AUR
3 65 large 1100 A F
4 75 large 1200 A S 190 3 days AUR
5 60 medium 700 P F
6 66 medium 1400 P F
7 63 small 800 P F
8 80 medium 700 P F
9 62 small 700 A S 180 lost  to 
follow up
10 62 medium 700 A F
11 58 medium 600 P F
12 63 medium 900 P S 100 9 months  Voiding
13 73 medium 700 P F
14 53 small 500 A F
15 66 small 650 A S 120 9.5 months AUR
16 65 medium 950 A F
17 74 large 1200 A F
18 53 medium 950 P F
19 70 medium 700 P F
20 82 large 1300 P F
21 66 medium 950 A S 100 11 months Voiding
22 70 medium 800 A S 60 lost  to 
follow up
23 62 small 850 P F
AGE PROSTATE 
SIZE
RESIDUAL 
VOLUME 
OF AUR
ALF/PLA SUC/FAIL PVR  IN 
SUCCESSFUL 
PATIENTS
FOLLOW 
UP
FOLLOW 
UP 
RESULT
24 65 medium 900 P F
25 59 medium 700 A F
26 54 small 500 P F
27 63 large 1000 P F
28 55 medium 750 A S 130 10.5 months Voiding
29 56 medium 600 A S 150 lost  to 
follow up
30 58 medium 850 A S 110 7 months TURP
31 59 medium 950 A S 60 8.5 months AUR
32 68 large 650 A S 190 21 days TURP
33 67 small 600 A S 50 12 months Voiding
34 64 large 800 A S 110 7.5 months Voiding
35 80 medium 650 A F
36 57 medium 500 P F
37 66 small 700 P S 50 8 months TURP
38 69 medium 900 P F
39 68 large 1100 P F
40 52 medium 500 A S 120 9 months Voiding
41 53 small 550 A F
42 65 medium 1100 A F
43 78 medium 1000 A F
44 54 medium 550 P F
45 70 medium 600 P F 
46 79 large 1000 P F
47 81 large 1100 P F
48 54 medium 800 A S 120 3 months AUR
AGE PROSTATE 
SIZE
RESIDUAL 
VOLUME 
OF AUR
ALF/PLA SUC/FAIL PVR  IN 
SUCCESSFUL 
PATIENTS
FOLLOW 
UP
FOLLOW 
UP 
RESULT
49 54 large 600 A F
50 52 medium 900 A F
51 71 large 1300 A S 160 6months AUR
52 55 small 950 P F
53 71 medium 550 P S 100 death  
54 55 small 500 A S 100 7 months AUR
55 55 medium 1200 A F
56 82 medium 700 A F
57 63 large 800 P S 150 6 months Voiding 
58 74 medium 1000 P F
59 53 medium 550 A S 130 5 months TURP
60 56 large 1400 A F
61 63 large 1400 A F
62 81 medium 1100 A F
63 53 large 600 P S 180 3 months TURP
64 62 small 1200 A S 110 9 months AUR
65 53 medium 550 P S 60 9.5 months Voiding
66 61 medium 750 A S 120 7 months Voiding
67 73 medium 900 A S 120 lost  to 
follow up
68 52 small 500 P S 140 4 months Voiding 
69 66 medium 1100 P S 140 3 months AUR
70 52 medium 950 P S 70 5 months Voiding 
71 54 medium 500 P S 100 lost  to 
follow up
 
72 67 medium 600 P F
AGE PROSTATE 
SIZE
RESIDUAL 
VOLUME 
OF AUR
ALF/PLA SUC/FAIL PVR  IN 
SUCCESSFUL 
PATIENTS
FOLLOW 
UP
FOLLOW 
UP 
RESULT
73 58 small 1200 A F
74 67 medium 950 A F
75 60 small 950 P F
76 67 medium 950 P S 100 2.5 months AUR
77 68 medium 1000 P F
78 76 large 1200 P F
79 73 medium 600 P F
80 55 small 600 A S 110 6 months Voiding
81 62 large 700 A S 140 5 months Voiding
82 64 medium 1000 A S 110 death
83 63 large 1200 A F
84 55 medium 1000 P S 50 lost  to 
follow up
 
85 58 medium 900 P F
86 63 small 800 P F
87 62 small 700 P F
88 61 medium 1200 P F
89 76 large 900 P F
90 57 large 650 A S 190 4 months Voiding
91 54 medium 550 A F
92 61 medium 600 A S 110 6 months Voiding
93 61 large 1000 A F
94 76 medium 800 A F
95 52 medium 600 P F
96 74 medium 1300 P F
97 64 medium 900 A S 100 5 months Voiding
AGE PROSTATE 
SIZE
RESIDUAL 
VOLUME 
OF AUR
ALF/PLA SUC/FAIL PVR  IN 
SUCCESSFUL 
PATIENTS
FOLLOW 
UP
FOLLOW 
UP 
RESULT
98 62 small 550 A F
99 80 large 700 A F
10
0
67 medium 700 P S 180 4.5 months AUR
10
1
64 medium 600 P F
10
2
76 large 950 P F
10
3
60 large 1200 A F
10
4
68 medium 700 P F
10
5
78 medium 1100 P F
10
6
82 large 1200 P F
10
7
60 medium 800 A F
10
8
76 large 1100 A F
10
9
56 large 600 P S 100 5 months Voiding 
110 62 medium 1200 P F
111 62 small 1300 A F
112 75 large 500 A F
113 65 large 1100 P F
114 61 medium 1300 P F
115 56 medium 600 P F
116 72 large 1300 P S 180 3 months Voiding 
117 67 medium 500 A F
118 76 large 600 A F
119 55 medium 1200 P F
12
0
64 large 700 P F
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